AASLD 2015

Fewer Medical Events Seen with Daclatasvir/Sofosbuvir in HCV GT3 Model

When all patients with hepatitis C virus (HCV) with genotype 3 (GT3) infection are treated with daclatasvir/sofosbuvir, substantially fewer medical events and lower medical costs are accrued” vs. scenarios in which no one is treated or treatment is limited to F3/F4 patients, results of a study using a Markov model presented at The Liver Meeting® 2015 concluded.

Activity, Work Impairment Scores Improved With 3D Regimens in HCV GT1

Interferon-free ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin showed a more favorable Work Productivity and Activity Impairment (WPAI) profile in treatment-naïve, non-cirrhotic, HCV GT1-infected patients vs. telaprevir + peginterferon/ribavirin (TPV + pegIFN/RBV), reported Yan Liu, MD, PhD, from AbbVie, North Chicago, IL at The Liver Meeting® 2015.

3D + R Lowers Liver Morbidity, Mortality Risks in HCV GT1 Post-Transplant

Patients with recurrent hepatitis C virus (HCV) genotype 1 (GT1) infection treated with the “3D+R” regimen post-transplant have a substantially lower likelihood of experiencing compensated or decompensated cirrhosis and death compared with the standard of care, 48 weeks of pegylated interferon plus ribavirin, or no treatment, a study reported at The Liver Meeting® 2015.